Medulloblastoma

The tumor was negative for a CDKN2A/B homozygous deletion and a TERT promoter mutation. Post-surgery, the patient showed immediate improvement in symptoms and was asymptomatic at the time of discharge and follow-up.

While challenges such as data scarcity and the "black box" nature of algorithms persist, innovative strategies offer potential solutions to AI application. AI serves as a transformative tool for personalized precision management, potentially bridging diagnostic disparities and optimizing clinical outcomes for children with central nervous system tumors.

P1/2, N=18, Active, not recruiting, Azienda Ospedaliera Universitaria Meyer IRCCS | Not yet recruiting --> Active, not recruiting

Integrating subgroup-specific genetic events with clinical features facilitates MB risk stratification, informs context-dependent radiotherapy consideration, and provides actionable candidates for prospective validation.

We sincerely thank Roesler and Isolan [...].

We read with great interest the recent study by Santana-Bejarano et al [...].

Although Yap1 regulates tumor immune cell infiltration and immunosuppression in both sexes, disruption of this pathway confers survival benefit only in males, not females. These findings highlight how oncogenic signaling intersects with tumor immunity and underscore the importance of considering biological sex in studies of cancer immunology and immunotherapy.

Using doxycycline-inducible shRNA constructs in HD-MB03 cells (a MYC-amplified Group MB model) to achieve SMARCA4 knockdown, we applied quantitative mass spectrometry to profile the resulting proteomic changes...The overexpression of top candidates like SMARCA2, CRABP2, FABP5, TAGLN2, CYP27A1, and SCP2 was validated in a separate validatory set. Our study reveals the proteomic landscape of Group 3 medulloblastoma following SMARCA4 loss, highlighting novel therapeutic targets for functional validation and exploitation.

P1, N=24, Not yet recruiting, University of Florida

He was treated with repeat radiation and temozolomide chemotherapy but developed recurrence with disseminated leptomeningeal disease thereafter. Based on these findings, the patient was treated with a MEK inhibitor, trametinib, and achieved durable disease control for 20 months until progression. This case underscores the importance of genomic profiling in RIGs and potential utility of molecularly targeted approaches in this population.

In mouse secondary palate development, OmiDos precisely identified a cell type-specific unlinked distal enhancer, elucidating its essential role in the regulation of epithelial cell differentiation and migration. The application of OmiDos to medulloblastoma revealed a potential role deficiency in driving partial closure of the distal enhancer region of Neurod1 may contribute to the progression of medulloblastoma from normal to tumor states.

Cross-species single-cell comparisons further show an association between Tox3 expression and cerebellum expansion during vertebrate evolution. Together, this work supports Tox3 as a critical Atoh1 coactivator in cerebellar development, tumorigenesis, and evolution, while providing an atlas and screening strategy as a valuable resource for exploring novel transcriptional regulators in organogenesis and tissue physiology.